Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Neuroblastoma
Study Phase
Phase 3
Study Completion Date
December 2013
NCT00033293Uploaded 09-30-2020
Access via NCI by Request
PDS UID: nci-data-429
A Phase III Randomized Trial of Intravenous Gammaglobulin Therapy for Patients With Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated With Chemotherapy and Prednisone
Provider Information
Provider Data DescriptionThere are three datasets: NCT00033293-D1 NCT00033293-D2 and NCT00033293-D3 for PMID 29376112. USI is the patient identifier in all datasets. NCT00033293-D1 There is one row for each patient enrolled on ANBL00P3. The dataset provides the information necessary to reproduce patient baseline characteristics, evaluability, treatment received, disease response, and survival.
SponsorChildren's Oncology Group
Data ProviderNational Cancer Institute
Clinical Trials.gov Information
Brief SummaryThis randomized phase III trial is studying cyclophosphamide, prednisone, and immunoglobulin to see how well they work compared to cyclophosphamide and prednisone alone in treating patients with abnormal trunk muscle movements associated with neuroblastoma. Drugs used in chemotherapy, work in different ways to stop tumor cells from dividing so they stop growing or die. Steroid therapy decreases inflammation. Combining chemotherapy and steroid therapy with immunoglobulin may be effective in treating abnormal muscle movement associated with neuroblastoma.
ConditionsLocalized Resectable Neuroblastoma
Localized Unresectable Neuroblastoma
Regional Neuroblastoma
Stage 4 Neuroblastoma
Stage 4S Neuroblastoma
Intervention TypeOther: Clinical Observation
Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Drug: Prednisone
Biological: Therapeutic Immune Globulin
Drug(s)Drug: Cyclophosphamide
Drug: Prednisone
Total Enrolled53
RandomizationRandomized
Blinding MethodNone (Open Label)
Arms InterventionArm I (chemotherapy, immunoglobulin therapy) - Experimental
Arm II (chemotherapy, observation) - Active Comparator
Secondary IDNCI-2009-00399
PubMed (PMID)29376112
Collaborator(s)National Cancer Institute (NCI)
Region(s)United States
Australia
Canada
Age Range8 Years and younger (Child)
Files: NCT00033293-D1
Data DictionaryNCT00033293-D1-Data-Dictionary_1.pdf
DATANCT00033293-D1-Dataset_1.csv
OTHERREADME.pdf
Files: NCT00033293-D2
Data DictionaryNCT00033293-D2-Data-Dictionary_1.pdf
DATANCT00033293-D2-Dataset_1.csv
OTHERREADME.pdf
Files: NCT00033293-D3
Data DictionaryNCT00033293-D3-Data-Dictionary_1.pdf
DATANCT00033293-D3-Dataset_1.csv
OTHERREADME.pdf
© 2023 Project Data Sphere
All rights reserved
Privacy PolicyTerms of Use